| scholarly article | Q13442814 |
| P2093 | author name string | Kevin R Flaherty | |
| John Yee | |||
| Eric S White | |||
| Mark B Orringer | |||
| Mark D Iannettoni | |||
| Shannon Carskadon | |||
| Douglas A Arenberg | |||
| Ashley Brant | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lung cancer | Q47912 |
| P304 | page(s) | 853-860 | |
| P577 | publication date | 2003-02-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis | |
| P478 | volume | 9 |
| Q36322394 | 25 Years On: A Retrospective on Migration Inhibitory Factor in Tumor Angiogenesis |
| Q34699934 | A critical regulatory role for macrophage migration inhibitory factor in hyperoxia-induced injury in the developing murine lung |
| Q30430715 | A gene expression ratio-based diagnostic test for bladder cancer |
| Q34612497 | A novel statistical prognostic score model that includes serum CXCL5 levels and clinical classification predicts risk of disease progression and survival of nasopharyngeal carcinoma patients |
| Q92783310 | ADAM17: An Emerging Therapeutic Target for Lung Cancer |
| Q35137492 | Adipose-derived stromal vascular fraction cells isolated from old animals exhibit reduced capacity to support the formation of microvascular networks |
| Q35753903 | Association between preeclampsia and the CXC chemokine family (Review). |
| Q37346143 | Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. |
| Q40724369 | CXC and CC chemokines as angiogenic modulators in nonhaematological tumors. |
| Q30432791 | CXC chemokines in cancer angiogenesis and metastases |
| Q33562564 | CXCL5 as a potential novel prognostic factor in early stage non-small cell lung cancer: results of a study of expression levels of 23 genes. |
| Q53555447 | CXCL5 overexpression is associated with late stage gastric cancer. |
| Q60931267 | Chemokines and Chemokine Receptors: Orchestrating Tumor Metastasization |
| Q30426904 | Chemokines as mediators of angiogenesis. |
| Q30438032 | Chemokines as mediators of neovascularization |
| Q30427886 | Chemokines as mediators of tumor angiogenesis and neovascularization |
| Q37032881 | Circulating levels of immune and inflammatory markers and long versus short survival in early-stage lung cancer |
| Q36488894 | Clinical utilization of chemokines to combat cancer: the double-edged sword |
| Q39198190 | Control of tumor-associated macrophage alternative activation by macrophage migration inhibitory factor |
| Q39953292 | Cooperative regulation of non-small cell lung carcinoma angiogenic potential by macrophage migration inhibitory factor and its homolog, D-dopachrome tautomerase |
| Q37400654 | Cyclic AMP-responsive element binding protein- and nuclear factor-kappaB-regulated CXC chemokine gene expression in lung carcinogenesis |
| Q38002982 | D-dopachrome tautomerase (D-DT or MIF-2): doubling the MIF cytokine family |
| Q35855285 | Diversity of the angiogenic phenotype in non-small cell lung cancer |
| Q44525447 | Elevated expression of macrophage migration inhibitory factor correlates with tumor recurrence and poor prognosis of patients with gliomas |
| Q37071916 | Expression of CD74, the receptor for macrophage migration inhibitory factor, in non-small cell lung cancer |
| Q36817369 | Expression of MIF and c-erbB-2 in endometrial cancer |
| Q35045522 | Expression of macrophage migration inhibitory factor is associated with enhanced angiogenesis and advanced stage in gastric carcinomas |
| Q36803606 | Expression of macrophage migration inhibitory factor relates to survival in high-grade osteosarcoma. |
| Q39177042 | Functional disruption of macrophage migration inhibitory factor (MIF) suppresses proliferation of human H460 lung cancer cells by caspase-dependent apoptosis |
| Q34928581 | Genomic profiles in stage I primary non small cell lung cancer using comparative genomic hybridization analysis of cDNA microarrays |
| Q35760546 | Increased epithelial and serum expression of macrophage migration inhibitory factor (MIF) in gastric cancer: potential role of MIF in gastric carcinogenesis |
| Q24793870 | Inhibition of macrophage migration inhibitory factor decreases proliferation and cytokine expression in bladder cancer cells |
| Q37287944 | Involvement of macrophage migration inhibitory factor in cancer and novel therapeutic targets |
| Q28396291 | Knockout of the tumor suppressor gene Gprc5a in mice leads to NF-kappaB activation in airway epithelium and promotes lung inflammation and tumorigenesis |
| Q38988535 | Macrophage Migration Inhibitory Factor (MIF): Biological Activities and Relation with Cancer |
| Q52672848 | Macrophage Polarization in Chronic Inflammatory Diseases: Killers or Builders? |
| Q35435019 | Macrophage migration inhibitory factor (MIF) enzymatic activity and lung cancer |
| Q36050495 | Macrophage migration inhibitory factor as a potential prognostic factor in gastric cancer |
| Q36999094 | Macrophage migration inhibitory factor manipulation and evaluation in tumoral hypoxic adaptation |
| Q24642663 | Macrophage migration inhibitory factor promotes colorectal cancer |
| Q34268934 | Macrophage migration inhibitory factor promotes tumor growth in the context of lung injury and repair |
| Q37187775 | Mechanisms of macrophage migration inhibitory factor (MIF)-dependent tumor microenvironmental adaptation |
| Q39283111 | Nanomedicine Strategies to Target Tumor-Associated Macrophages |
| Q36368238 | Negative regulation of AMP-activated protein kinase (AMPK) activity by macrophage migration inhibitory factor (MIF) family members in non-small cell lung carcinomas |
| Q37904904 | Nuclear factor-κB: a key regulator in health and disease of lungs |
| Q34768343 | PPAR-gamma activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer |
| Q35050740 | Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma |
| Q92481979 | Pleiotropic role of macrophage migration inhibitory factor in cancer |
| Q38434316 | Prediction of optimal gene functions for osteosarcoma using network-based- guilt by association method based on gene oncology and microarray profile |
| Q37462505 | Proangiogenic TIE2(+)/CD31 (+) macrophages are the predominant population of tumor-associated macrophages infiltrating metastatic lymph nodes |
| Q38100750 | Proteomic biomarkers in lung cancer |
| Q28081711 | Role of macrophage migration inhibitory factor in age-related lung disease |
| Q36016138 | Serum biomarker profiles as diagnostic tools in lung cancer |
| Q34944820 | Stromal-dependent tumor promotion by MIF family members |
| Q37406057 | SubpathwayMiner: a software package for flexible identification of pathways |
| Q33898524 | The low expression of miR-451 predicts a worse prognosis in non-small cell lung cancer cases |
| Q37863514 | The role of chemokines and their receptors in angiogenesis |
| Q36875749 | The role of macrophage migration inhibitory factor in maintaining the immune privilege at the fetal-maternal interface. |
| Q36285576 | Upregulation of C-X-C chemokine receptor type 1 expression is associated with late-stage gastric adenocarcinoma |
Search more.